NVIDIA says Lilly has brought LillyPod online, a pharma-owned AI factory built with 1,016 Blackwell Ultra GPUs and more than 9,000 petaflops of AI performance. The platform is intended to accelerate model training and simulation across genomics, small molecules, and clinical-development workflows.
A research-sharing post in r/MachineLearning presented Flower, a neural PDE architecture centered on learned coordinate warps. The author-reported results claim strong performance against FNO, U-Net, and attention baselines across The Well-style benchmarks.
NVIDIA's 2026 healthcare and life sciences survey shows active AI use at 70%, up from 63% in 2024. Executives reported strong business impact, with 85% citing revenue gains and 80% citing cost reduction from AI initiatives.
Spanish researchers found that the blood-based biomarker p-tau217 can raise Alzheimer's diagnostic accuracy to 94.5%, potentially enabling early, accessible diagnosis without invasive procedures.
Spanish researchers found that the blood-based biomarker p-tau217 can raise Alzheimer's diagnostic accuracy to 94.5%, potentially enabling early, accessible diagnosis without invasive procedures.
Isomorphic Labs, the DeepMind spin-off focused on AI-driven drug discovery, has unveiled a new AI that scientists are calling a generational leap comparable to AlphaFold.
ASML has announced a breakthrough in EUV light source technology that could produce 50% more semiconductor chips from the same wafer by 2030.
Element Biosciences hit the $100 genome milestone in February 2026 — a one-million-fold cost reduction from the $100M price tag of the Human Genome Project in 2000, far outpacing Moore's Law.
Google DeepMind spin-off Isomorphic Labs published a technical report on IsoDDE, a proprietary drug discovery AI that scientists are comparing to a hypothetical AlphaFold 4. The model excels at predicting protein-drug binding and has secured billion-dollar deals with J&J, Eli Lilly, and Novartis.
San Diego startup Element Biosciences has achieved the sub-$100 human genome milestone in February 2026—a 1,000,000x cost reduction from the Human Genome Project in 2000, far outpacing Moore's Law and signaling a new era of mass-market personalized medicine.
Google DeepMind announced AlphaGenome on June 25, 2025, alongside a Nature publication and a preview API for non-commercial research. The model processes up to 1 million DNA letters and jointly predicts diverse regulatory properties and variant effects from a single framework.
A highly discussed Hacker News post tracked Chrome’s security update for CVE-2026-2441 (High, CSS use-after-free). Google states an exploit exists in the wild and ships patched stable versions across desktop platforms.